APA (7th ed.) Citation

AH, B., SJ, B., I, D., LD, A., & V, S. (2019). Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clinical pharmacology in drug development, 8(4), 426. https://doi.org/10.1002/cpdd.689

Chicago Style (17th ed.) Citation

AH, Burstein, Brantley SJ, Dunn I, Altstiel LD, and Schmith V. "Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis." Clinical Pharmacology in Drug Development 8, no. 4 (2019): 426. https://doi.org/10.1002/cpdd.689.

MLA (9th ed.) Citation

AH, Burstein, et al. "Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis." Clinical Pharmacology in Drug Development, vol. 8, no. 4, 2019, p. 426, https://doi.org/10.1002/cpdd.689.